- AuthorisedTherapeutic exploratory (Phase II)
Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma.
This study is looking at a new, stronger chemotherapy treatment for people with high-risk Ewing Sarcoma. It combines medicines like Treosulfan and Melphalan to see how safe and effective they are. The aim is to find better ways to stop this cancer from coming back.
For: Ewing SarcomaItaly - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
For: High-Risk Neuroblastoma · Patient With Insufficient Response ChemoimmunotherapyAustralia · Austria · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
This study compares a new cell therapy (Tisagenlecleucel) with standard treatments for adults with an aggressive type of lymphoma that has come back or not responded to previous therapy. Researchers want to see which treatment is better at stopping the cancer from growing.
For: Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomaNetherlands · Spain · Norway - RecruitingPHASE2, PHASE3
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
This study looks for better ways to treat B-cell non-Hodgkin Lymphoma (B-NHL) in children and young people when initial treatments haven't worked or the cancer has returned. It tests new medicines to see if they are safe and effective, aiming to improve chances of recovery.
For: B-cell Non Hodgkin LymphomaAustralia · Austria · Belgium - Active not recruitingPHASE3
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
This study compares two chemotherapy treatments for germ cell tumours that have returned or didn't respond to previous treatment. It looks at a standard chemotherapy plan versus a stronger plan with a stem cell transplant to see which works better.
For: Germ Cell Tumor · Teratoma · ChoriocarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE2
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
This study looks at a new combination of treatments for a type of lymphoma called diffuse large B-cell lymphoma. It combines standard chemotherapy with a newer drug called pembrolizumab to see if it works better for people whose lymphoma has come back or hasn't responded to previous treatment.
For: Diffuse Large B Cell LymphomaUnited Kingdom - Active not recruitingPHASE3
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
This study compares two treatments for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded well to initial treatment. One treatment is a standard chemotherapy, and the other adds a new drug, polatuzumab vedotin, to that standard treatment.
For: Relapsed Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-Cell LymphomaAustria · Germany · Spain - RecruitingPHASE3
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
This study looks at the best way to treat penile cancer that has spread to nearby lymph nodes. It compares surgery alone with surgery after chemotherapy or chemoradiotherapy. It also checks if extra surgery in the pelvis helps prevent cancer from coming back.
For: Squamous Cell Carcinoma of the Penis, Usual TypeUnited States · United Kingdom - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)
This study looks at a new cell therapy called Tecartus for adults with a type of blood cancer called Richter Transformation that has come back or not responded to previous treatments. It aims to see how well it works and if it's safe.
For: Relapsed/refractory Richter Transformation (RT)France · Germany · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy C – Relapsed/Refractory Burkitt Lymphoma (BL)
This study is looking at a new treatment called Tecartus for adults in the UK with a specific type of blood cancer called Burkitt Lymphoma. It's for patients whose cancer has come back or hasn't responded to previous treatments. Researchers want to see how well Tecartus works.
For: Relapsed/Refractory Burkitt Lymphoma (BL)Netherlands · France · Austria - AuthorisedTherapeutic confirmatory (Phase III)
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
This study looks at treating a children's cancer called neuroblastoma. We want to find the best way to treat children who have a lower chance of a severe form of the disease. This will help doctors choose the right treatment to give children the best chance of getting better.
For: low and intermediate risk neuroblastomaGermany - RecruitingPHASE1, PHASE2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
This study, FaR-RMS, is for children and adults with a type of cancer called rhabdomyosarcoma. It's looking for better ways to treat both newly diagnosed and returning cancer, using different combinations of medicines and radiotherapy.
For: RhabdomyosarcomaAustralia · Austria · Belgium